Intellia Therapeutics Inc (NTLA)
R&D Expense Growth
-16.61%
Fiscal year · Period ending:
NTLA R&D Expense Growth
Latest reported-16.61%period ending
Latest reported-16.61%period ending
NTLA FY R&D Growth (YoY) (0.00% → -16.61%)
Latest values, visible window
High-resolution chart · PNG
NTLA r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -16.6091% | |
| 7.1809% | |
| 3.593% | |
| 82.7529% | |
| 52.7891% | |
| 38.7361% | |
| 21.6552% | |
| 31.7353% | |
| 112.4592% | |
| 185.0492% | |
| 4.0037% | |
| 0% |